Newron Pharmaceuticals SpA
| Società per azioni | |
| Traded as | SIX: NWRN |
| ISIN | 🆔IT0004147952 |
| Industry | Pharmaceutical research |
| Founded 📆 | |
| Founder 👔 | |
| Headquarters 🏙️ | , , |
Area served 🗺️ | |
| Members | |
Number of employees | |
| 🌐 Website | http://www.newron.com |
| 📇 Address | |
| 📞 telephone | |
Newron Pharmaceuticals is an Italian pharmaceutical research company founded in 1999 and based in Bresso, near Milan. Its shares are traded on the Swiss Stock Exchange.
Safinamide, a drug against Parkinson's disease, was approved by the EU and Switzerland in 2015, and in 2017, by the U.S. FDA. Drugs in development are ralfinamide against neuropathic pain, and evenamide to treat schizophrenia.
The largest shareholder of Newron is Zambon, which is also headquartered in Bresso, with 4.41% of the voting rights.[1]
Sources
- ↑ "Annual Report, 2022" (PDF). Retrieved 2024-01-29., page 17
This article "Newron Pharmaceuticals 2" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Newron Pharmaceuticals 2. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
